Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes. // Endocrinology & Metabolism Clinics of North America. – URL: https://www.sciencedirect.com/science/article/pii/S0889852926000381?dgcid=rss_sd_all
Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes. Endocrinology & Metabolism Clinics of North America. https://www.sciencedirect.com/science/article/pii/S0889852926000381?dgcid=rss_sd_all
“Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes.” Endocrinology & Metabolism Clinics of North America.
@article{article44536,
title = {Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes},
journal = {Endocrinology \& Metabolism Clinics of North America},
url = {https://www.sciencedirect.com/science/article/pii/S0889852926000381?dgcid=rss_sd_all}
}